medigraphic.com
ISSN 1608-8921 (Print)

2016, Number 2

<< Back Next >>

Gaceta Médica Espirituana 2016; 18 (2)

Theoretical framework on retinopathy of prematurity and research criteria

Rodríguez RM, Concepción PJA

Language: Spanish
References: 26
Page:
PDF size: 164.64 Kb.


ABSTRACT

Background: The retinopathy of the prematurity is a vasoproliferative microangiopathy that is unchained in preterm children and with factors of risk for its development. It can advance, of not being detected and treated, toward the visual handicap and even the blindness, of there the importance of their inquire criteria. It was carried out a systematic revision on this relatively young topic in ophthalmology, in the database Medline that involved the last decade, to be this the stage in that Cuba has developed the inquire criteria work and treatment of the illness. Objective: To upgrade the knowledge about the retinopathy of the prematurity and its investigation approaches. Development: In the world there have been carried out multicentre studies for its best understanding and handling; and it have become unified approaches for its classification, being the main factors of risk to those that associates the low gestational age at birth, the extreme low weight, the ventilation and oxygen employment, among others. Several treatments exist to avoid the blindness for retinopathy of the prematurity, being the laser the more used at the moment, combining in many cases with therapeutic novel as the vitrectomy and the angiogenic. As for the investigation approaches uniformity doesn't exist in the world, but Cuba has a National Protocol for its handling that guarantees its opportune diagnosis and an immediate treatment. Conclusions: The retinopathy of the prematurity is an ophthalmologic illness that constitutes priority in Cuba, existing in the country a national protocol for its handling and this way to avoid the visual damage that can cause.


REFERENCES

  1. Di Renzo et al. ACOG, practice bulletin. The journal of maternal-fetal and neonatal medicine. 2012;24(5): 659-67.

  2. Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, Zin A. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate and high levels of development: implications for screening programs. Pediatrics [Internet]. 2005 [cited: 2016/01/16];115(5):e518–25. Available from: http://pediatrics.aappublications.org/content/115/5/e518.long

  3. Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res [Internet]. 2013 [cited: 2016/01/16];74(Suppl 1):35–49. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873709/

  4. Mier M, Fuentes J, Rodriguez M, Arencibia D, Herrera B. Resultados del programa cubano de prevención de ceguera por ROP. Visión Pan-América. 2008;7(1):7-8.

  5. Eguía Martínez F, Río Torres M, Capote Cabrera A. Manual de diagnóstico y tratamiento en oftalmología. La Habana: Ecimed; 2009.

  6. Rodríguez Rodríguez M, Díaz Guzmán EC, Concepción Pacheco JA. Estudio clínico epidemiológico de la Retinopatía de la Prematuridad en la provincia de Sancti Spíritus. 2005-2010. Rev. Infociencia. 2014; Vol 18, (1)

  7. OMS. Ceguera y discapacidad visual. Nota Descriptiva No 282. Ginebra: OMS;2014. Disponible en: http://www.who.int/mediacentre/factsheets/fs282/es/

  8. Terry TL. Extreme prematurity and fibroplastic overgrowth of persistent vascular sheath behind cristalline lens. Am J Opthalmol. 1942; 25: 203-204.

  9. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol [Internet]. 2005 [cited: 2016/01/16] ;123(7):991–9. Available from: http://archopht.jamanetwork.com/article.aspx?articleid=417157

  10. Dobson V, Quinn GE, Summers CG, Hardy RJ, Tung B. Visual acuity at 10 years in cryotherapy for retinopathy of prematurity study eyes: Effect of retinal residua of retinopathy of Prematurity. Arch ophthalmol [Internet].2006 [cited: 2016/01/16]; 124 (2): 311-18. Available from: http://archopht.jamanetwork.com/article.aspx?articleid=417496

  11. Jordan CO. Retinopathy of Prematurity. Pediatr Clin North Am [Internet]. 2014[cited: 2016/01/16] ; 61: 567–577 http://www.sciencedirect.com/science/article/pii/S0031395514000182

  12. The Stop-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics [Internet]. 2000[cited: 2016/01/16]; 105(2):295–310. Available from: http://pediatrics.aappublications.org/content/105/2/295.long

  13. González Viejo I, Ferrer Novella C, Pueyo Royo V. El algoritmo WINROP y otras novedades en el cribado de la retinopatía del premature. Arch Soc Esp Oftalmol [Internet]. 2013 [ciado: 2016/01/16];88(2):43–44. Disponible en: http://www.elsevier.es/es-revista-archivos-sociedad-espanola-oftalmologia-296-articulo-el-algoritmo-winrop-otras-novedades-S0365669113000695?redirectNew=true

  14. González Viejo I, Ferrer Novella C, Pueyo Royo V, García-Ormaechea Y, Prieto E. Visual síndrome of prematurity. Arch Soc Esp Oftalmol [Internet]. 2014 [citado: 2016/01/13];89(11):429–430. Disponible en: http://www.elsevier.es/es-revista-archivos-sociedad-espanola-oftalmologia-496-articulo-visual-syndrome-prematurity-S2173579414002163?redirectNew=true

  15. Fijalkowski N, Zheng LL, Henderson MT, Wang SK, Wallenstein MB, Leng T, et al. Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): Five years of screening with telemedicine. Ophthalmic Surg Lasers Imaging Retina [Internet]. 2014 Mar-Apr [cited: 2016/01/16];45(2):106-13. Available from: http://www.healio.com/ophthalmology/journals/osli/2014-3-45-2/%7Bf8efa010-8751-40e9-8313-504015229f84%7D/stanford-university-network-for-diagnosis-of-retinopathy-of-prematurity-sundrop-five-years-of-screening-with-telemedicine

  16. Kim J, Kim SJ, Chang YS, Park WSKim J. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina [Internet]. 2014 [cited: 2016/01/16];34(1):77–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=Combined+intravitreal+bevacizumab+injection+and+zone+I+sparing+laser+photocoagulation+in+patients+with+zone+I+retinopathy+of+prematurity.+Retina.+2014

  17. Mintz-Hittner HA. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmic [Internet]. 2012 [cited: 2016/01/16];22(5):685–6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=Intravitreal++pegaptanib++as++adjunctive+treatment++for++stage++3%2B++ROP++shown++to++be++effective++in++a+prospective%2C++randomized%2C++controlled++multicenter++clinical++trial.+Eur++J++Ophthalmol+.+2012

  18. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol [Internet]. 2012 [cited: 2016/01/16];153(2):327–33. Available from: http://www.sciencedirect.com/science/article/pii/S0002939411005824

  19. Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol [Internet]. 2014 [cited: 2016/01/16]; 98(4):507-129. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963534/

  20. Bancalari MA, Schade YR, Pena ZR, Pavez PN. Intravitreal bevacizumab as single drug therapy for retinopathy of prematurity in 12 patients. Arch Argent Pediatr [Internet]. 2014 Apr [cited: 2016/01/16];112(2):160-3. Available from: http://www.sap.org.ar/docs/publicaciones/archivosarg/2014/v112n2a09.pdf

  21. Alba LE, Zaldua RA, Masini RA. Uso off-label de bevacizumab intravítreo en retinopatía del prematuro severa. Arch Soc Esp Oftalmol [Internet]. 2015 [cited: 2016/01/16];90(2):81–86. Disponible en: http://www.elsevier.es/es-revista-archivos-sociedad-espanola-oftalmologia-296-articulo-uso-off-label-bevacizumab-intravitreo-retinopatia-S0365669114003566

  22. Fierson WM. Screening examination of premature infants for retinopathy of prematurity. Pediatrics [Internet]. 2013 [cited: 2016/01/16]; 131(1):189–95 Available from: http://pediatrics.aappublications.org/content/131/1/189.long

  23. Protocolo-Org. Origen del término protocolo. El Protocolo en la historia. [Internet]. [Publicado: 11/07/2003; Modificado el 19/06/2016]. [citada: 2016/07/01]. Disponible en: https://www.protocolo.org/miscelaneo/reportajes/origen_del_termino_protocolo_el_protocolo_en_la_historia.html

  24. American academy of pediatrics. Screening examination of premature infants for retinopathy of prematurity. Pediatrics [Internet]. 2006 [cited: 2016/01/16];117(2):572-6. Available from: http://pediatrics.aappublications.org/content/pediatrics/117/2/572.full.pdf

  25. Tomé VA, Vieira JF, Oliveira LB, Pinto Rde M, Abdallah VO. Estudo da retinopatia da prematuridade em um hospital universitário. Arq Bras Oftalmol [Internet]. 2011[cited: 2016/01/16];74(4):279-82. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492011000400010&lng=en&nrm=iso&tlng=en

  26. Díaz Guzmán EC, Rodríguez Rodríguez M, Concepción Pacheco JA. Estudio clínico epidemiológico de la baja visión en la provincia de Sancti Spíritus. 2005 - 2010. Rev. Infociencia. 2014;18(2).




2020     |     www.medigraphic.com